Floatz logo

Lonafarnib

Supratentorial Cancer

M.D. Anderson Cancer CenterSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Supratentorial Cancer cohort.

Asset / SponsorPhaseRating
G 207
Gregory K. Friedman, MD
Phase 1CC
Voluven
National Taiwan University Hospital
N/ANR

Same molecule, other indications

Lonafarnib is also rated in:

Hutchinson-Gilford progeria syndromeDormant
B
Indicative ·
58 / 100
View asset →
metastatic neoplasmDormant
B
Indicative ·
57 / 100
View asset →
renal pelvis/ureter urothelial carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →